bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

bluebird bio (BLUE) Tops Q4 EPS by 76c, Updates on BLA Submission for Lovo-Cel for Sickle Cell Disease

March 29, 2023 7:13 AM EDT

bluebird bio (NASDAQ: BLUE) reported Q4 EPS of $0.38, $0.76 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $62 thousand versus the consensus estimate of $884.67 thousand.

LOVO-CEL

BLA submission anticipated following response from FDA on analytical comparability data in the coming... More